|Day Low/High||112.47 / 114.35|
|52 Wk Low/High||94.59 / 141.86|
Stocks edged higher in cautious gains after Monday's rally pulled the Dow Jones Industrial Average and S&P 500 to their best gains in six months.
It is good to be sitting in for Doug Kass here on the Daily Diary as we look to end the trading week on a positive note. It is also good to see the Yankees start to win close games again after losing so many of them in the weeks leading into the All...
A quantitative upgrade and chart patterns may do the trick.
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.
But I don't have a lot of confidence in this market beyond the intraday action.
Alexion Pharmaceuticals presents a tradeable countertrend opportunity.
"If you work for a living, why do you kill yourself working?" -- Tuco, The Ugly: " The Good, the Bad and the Ugly" https://www.youtube.com/watch? v=AFa1-kciCb4 No "Takeaways" today as the action was another painfully boring, uneventful and with litt...
If you want to stay active, you'll have to do more homework.
"There are two kinds of spurs, my friend. Those that come in by the door; those that come in by the window.." -- Tuco, " The Good, the Bad and the Ugly" No "Takeaways" today as the action was kinda boring, uneventful and with little individual stock...
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...
Alexion paid $8.4 billion to acquire Synageva in hopes that its leading rare disease drug would become a billion-dollar product.
Start 2017 on the right foot by selling your holdings in these five stocks.
Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.
Jim Cramer explains the recent moves in biotechs and comments on reports regarding a Justice Department investigation into generic drug makers.
Here's a window into what institutional investors may be doing and how to profit from that.
Too many turn bearish too quickly just because they can't find any entry points.
Shares of Biogen and Alexion Pharmaceuticals took a hit Tuesday after their promising new products failed clinical trials.
U.S. indices are up as oil continues its climb past $50 a barrel.
Crude prices were also falling following the BOJ's decision to keep its monetary policy unchanged.
The next potential support levels are the $120 and $100 areas from 2013.